Yasin Akbari is an associate in the firm's internationally recognized Life Sciences group. Her practice covers a diverse range of complex transactions in the life sciences and technology industries, with a focus on mergers and acquisitions, royalty-based financings and other strategic investments, and capital markets transactions. She also acts as a day-to-day advisor to public and private companies, providing guidance on corporate governance, SEC reporting, and stock exchange compliance.

Yasin is a member of the Boston Bar Association and the Women’s Bar Association. She joined Goodwin in 2015.

Areas of Practice
业务范围
Domaines D’Expertise
TÄTIGKEITSFELDER

Experience

工作经历

EXPÉRIENCE

ERFAHRUNG

Representative Matters

代表事项

REFERENZMANDATE

Mergers and Acquisitions

Yasin has broad experience representing clients in mergers, acquisitions, business combinations, and spin-offs, including:

  • Blueprint Medicines in its acquisition of Lengo Therapeutics for $250 million upfront and up to $465 million in total
  • bluebird bio in the spin-off of its oncology programs and portfolio into 2seventy bio
  • CathWorks in its acquisition option agreement with Medtronic for up to $585 million upfront plus post-closing earn-out payments
  • Corvidia Therapeutics in its sale to Novo Nordisk for $725 million upfront and up to $2.1 billion in total
  • Spark Therapeutics in its $4.8 billion sale to Roche
  • ANA Therapeutics in its sale to NeuroBo Pharmaceuticals
  • Twilio in its $3 billion acquisition of SendGrid
  • Keryx Biopharmaceuticals in its $1 billion merger with Akebia Therapeutics
  • Consonance-HFW Acquisition Corp., a SPAC formed by Consonance Capital Management, in its business combination with Surrozen
  • Clarus Therapeutics in its business combination with Blue Water Acquisition Corporation
Royalty-Based Financings, Product Development Financings, and Strategic Investments

Yasin has special expertise in royalty-based financings, including sales of synthetic royalty interests, and product development financings. She has represented numerous companies and leading investors in this space, including:

  • Alnylam Pharmaceuticals in its strategic financing collaboration with Blackstone Life Sciences, valued at $2 billion
  • Blueprint Medicines in:
    • its strategic financing collaboration with Sixth Street Partners for up to $910 million; and
    • its sale of royalties on Gavreto to Royalty Pharma for $175 million upfront plus up to $165 million in milestone payments
  • Blackstone Life Sciences in its €300 million strategic financing collaboration with Sanofi, to support the clinical development of a subcutaneous formulation of Sarclisa
  • Carlyle and Abingworth, working with their development company Launch Therapeutics, in their non-dilutive financing of Opthea of up to $170 million to support the late-stage development and pre-commercialization of OPT-302
  • Abingworth in its $100 million financing of CymaBay Therapeutics to support the clinical development of seladelpar
  • Royalty Pharma in multiple transactions, including:
    • its $2.025 billion strategic financing partnership with MorphoSys;
    • its $827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta;
    • its purchase of worldwide royalties on sales of tazemetostat from Eisai and Epizyme and concurrent $100 million equity investment in Epizyme;
    • its $320 million acquisition of Ultragenyx’s royalties on European sales of Crysvita;
    • its $100 million purchase of a synthetic royalty on sales of Nurtec from, and equity investments of up $250 million in, Biohaven;
    • its $94 million acquisition of MGH’s royalties on sales of Entyvio;
    • its $220 million acquisition of a partial interest in AiCuris’ royalties on Prevymis; 
    • its $255 million acquisition of Agios’ royalties on Idhifa;
    • its $175 million purchase of a synthetic royalty on sales of Trodelvy from, and equity investment of $75 million in, Immunomedics; and
    • its acquisition of royalties on sales of Erleada
  • Nektar Therapeutics in:
    • its $150 million capped sale of royalties on Movantik, Adynovate and Rebinyn to Healthcare Royalty Partners; and
    • its $150 million financing and co-development collaboration with SFJ Pharmaceuticals to support the clinical development of bempegaldesleukin (BEMPEG)
  • RTW Investments in its strategic financing and licensing collaboration with Cytokinetics, valued at $200 million upfront, focused on the development of CK-274
  • R-Bridge Healthcare Fund, an affiliate of CBC Group, in:
    • its $60 million loan to Paratek Pharmaceuticals, backed by royalties on sales of omadacycline in greater China and a revenue interest in U.S. sales of Nuzyra; and
    • its $40 million loan to Trevena, backed by royalties on sales of oliceridine in greater China and a revenue interest in U.S. sales of Olinvyk
  • AnaptysBio in its sale to DRI Capital of royalties on sales of Zejula for $35 million upfront and a $10 million milestone payment
  • Cornerstone OnDemand in its $300 million strategic investment led by Silver Lake
  • Chiasma in its $75 million revenue interest financing with Healthcare Royalty Partners to support the late-stage development and commercial launch of Mycapssa
  • Concert Pharmaceuticals in its sale to BVF Partners and RA Capital of a partial interest in potential future royalties on sales of AVP-786
  • Hansa Biopharma in its $70 million financing with NovaQuest to support the development and commercialization of imlifidase
Capital Markets

Yasin’s recent client representations in initial public offerings, follow-on offerings, PIPE financings, and at-the-market (ATM) programs include:

  • 2seventy bio in its $170 million March 2022 PIPE financing
  • Cabaletta Bio in its $75 million initial public offering
  • TCR2 Therapeutics in its $75 million initial public offering
  • COMPASS Pathways in its $144 million April 2021 public offering and $150 million at-the-market program
  • bluebird bio in its December 2016, December 2017, June 2017, July 2018 and May 2020 public offerings, raising over $2.5 billion
  • Blueprint Medicines in its December 2016, December 2017, April 2019 and January 2020 public offerings, raising over $1 billion, and its $300 million at-the-market program
  • Revolution Healthcare Acquisition Corp., a SPAC formed by General Catalyst and ARCH Venture Partners, in its March 2021 $500 million initial public offering
  • Consonance-HFW Acquisition Corp. in its November 2020 $80 million initial public offering

Recognition

While attending law school, Ms. Akbari served as a note editor for the International and Comparative Law Review and chaired the Women's Law Center.

In The News

相关新闻

ACTUALITÉS

MELDUNGEN

Credentials

专业资格

RÉFÉRENCES

WERDEGANG

Education

J.D., 2015
Boston College Law School
(cum laude)
M.A., 2011
Yale University
B.A., 2010
Johns Hopkins University

Admissions

Bar

Massachusetts
Profile Image
Get In Touch
联系我们
NOUS CONTACTER
Kontakt
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
搜寻其他律师
Recherche par Pratique
ANWALTSSUCHE